NJ State Employees Deferred Compensation Plan Has $573,000 Stake in Mylan N.V. (MYL)
NJ State Employees Deferred Compensation Plan continued to hold its position in Mylan N.V. (NASDAQ:MYL) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,750 shares of the company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in Mylan N.V. were worth $573,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. increased its position in Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock worth $1,513,696,000 after buying an additional 37,728,274 shares during the period. Pzena Investment Management LLC purchased a new position in Mylan N.V. during the first quarter worth about $283,158,000. TIAA CREF Investment Management LLC increased its position in Mylan N.V. by 187.3% in the first quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock worth $168,268,000 after buying an additional 2,813,653 shares during the period. Morgan Stanley increased its position in Mylan N.V. by 82.6% in the first quarter. Morgan Stanley now owns 4,174,499 shares of the company’s stock worth $162,765,000 after buying an additional 1,888,905 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Mylan N.V. by 2.6% in the first quarter. Wellington Management Group LLP now owns 46,373,108 shares of the company’s stock valued at $1,808,088,000 after buying an additional 1,165,852 shares during the last quarter. Institutional investors and hedge funds own 70.19% of the company’s stock.
Shares of Mylan N.V. (NASDAQ MYL) opened at 32.00 on Tuesday. The stock has a market capitalization of $17.15 billion, a PE ratio of 31.97 and a beta of 1.27. Mylan N.V. has a 52-week low of $31.47 and a 52-week high of $50.40. The company’s 50 day moving average price is $38.42 and its 200 day moving average price is $39.28.
Mylan N.V. (NASDAQ:MYL) last announced its earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.01. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The company had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period in the prior year, the company posted $0.76 EPS. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. On average, equities research analysts anticipate that Mylan N.V. will post $5.16 EPS for the current year.
MYL has been the subject of several analyst reports. Wells Fargo & Company restated a “market perform” rating and set a $40.00 price target on shares of Mylan N.V. in a report on Friday, April 14th. Royal Bank Of Canada restated a “sector perform” rating and set a $46.00 price target (down from $48.00) on shares of Mylan N.V. in a report on Monday, April 17th. Deutsche Bank AG reduced their price target on Mylan N.V. from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, April 18th. BMO Capital Markets initiated coverage on Mylan N.V. in a report on Monday, May 1st. They set an “outperform” rating and a $50.00 price target for the company. Finally, Zacks Investment Research downgraded Mylan N.V. from a “hold” rating to a “sell” rating in a report on Monday, May 15th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $50.21.
In related news, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider now directly owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $1,000,000.00. Following the transaction, the president now directly owns 799,855 shares in the company, valued at $31,994,200. The disclosure for this sale can be found here. Corporate insiders own 0.69% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.